Sydney, Australia 10 April 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O’Bryan-Tear has joined Clarity’s Board following his recent appointment to their Scientific Advisory Board in August 2018 (Clarity Announcement dated 23 August 2018). Dr O’Bryan-Tear joined the pharmaceutical industry in…
Sydney, Australia 3 April 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce changes to its senior executive team to help its focus on commercial development and execution of its pipeline of radiopharmaceutical products for the treatment of children and adults with cancer. Dr Matt Harris,…
Sydney, Australia 26 March 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is delighted to announce that Dr Thomas Ramdahl will join Clarity’s Board. Dr Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and the first CEO of…
Sydney, Australia 28 February 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is delighted to announce that Dr Robert Miller will be working part-time as Consultant Chief Medical Officer. Dr Miller joined the pharmaceutical industry in 1988 and is a Managing Partner in Artemida Pharma Limited a drug development consultancy…
Sydney, Australia 18 February 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has raised a total of $8,965,959.75. This includes the previously announced strategic investment of $5,000,002.75 from GenesisCare, the largest private provider of cancer treatment in Australia and Europe, and an additional $3,965,957.00…
Sydney, Australia 11 October 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Prof Jason S. Lewis has joined their scientific advisory board. Jason S. Lewis, PhD, serves as Vice Chair for Research in the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK),…
Clarity Pharmaceuticals was featured in AUSinnovates, a media project driven by gemaker that aims to stimulate research and innovation in Australia. The article sheds light on the story behind Clarity’s SAR Technology, discusses Clarity’s product pipeline and talks about the benefits of a collaborative approach to drug development. Read the full article here: https://www.ausinnovates.com.au/clarity/
Sydney, Australia 13 September 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of cancer, cardiovascular disease and fibrosis, has received a strategic investment of $5 million from GenesisCare, the largest private provider of cancer treatment in Australia and Europe. The funds will go towards the development of Clarity’s clinical pipeline, aligning with…
Sydney, Australia 23 August 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O’Bryan-Tear has joined their scientific advisory board. Dr O’Bryan-Tear joined the pharmaceutical industry in 1986 where he has spent 30 years in clinical development, medical management and commercial roles.…
Sydney, Australia 10 July 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at Royal North Shore Hospital in Sydney has been completed and recruitment has commenced for its SARTATE™ clinical trial. Clarity’s SARTATE™ trial is a Peptide Receptor Radionuclide Therapy clinical trial…